How Assistance Works
Streamlining our patient’s specialty pharmacy experience with unmatched full-service convenience
-
1. Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
-
2. Transfer Prescription to AmeriPharma®
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
-
3. Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
-
4. Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma® Specialty Care has secured $55 million in financial assistance for our patients.
-
5. Nursing Care Coordination If Needed
AmeriPharma® puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
-
6. Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Eltrombopag?
Eltrombopag (brand name Promacta) is an oral medication prescribed to increase platelet counts in people with certain blood disorders, including chronic immune thrombocytopenia (ITP). Platelets are blood cell fragments that help form clots and stop bleeding.
In 2008, eltrombopag (Promacta) received approval from the Food and Drug Administration (FDA) to treat certain adults with chronic immune thrombocytopenia (ITP). The FDA later expanded its approved uses to include other conditions associated with low blood cell counts. Common side effects of this drug may include nausea, headache, diarrhea, urinary tract infections, upper respiratory tract infections, and fever.
Eltrombopag (Promacta): FDA-Approved Uses
The FDA has approved eltrombopag (Promacta) for several conditions associated with low platelet or blood cell counts, including persistent or chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older. Its approved uses include:
- To treat adults and children aged 1 year and older with persistent or chronic ITP who have not responded adequately to corticosteroids, immunoglobulins, or splenectomy. It should be used only in patients whose condition and degree of thrombocytopenia increase their risk of bleeding.
- To treat low platelet counts in patients with chronic hepatitis C who need to start and maintain interferon-based therapy.
- As first-line treatment in combination with standard immunosuppressive therapy for adults and children aged 2 years and older with severe aplastic anemia (SAA).
- To treat patients with severe aplastic anemia (SAA) who have not responded adequately to immunosuppressive therapy.
Promacta (eltrombopag) is not recommended to treat patients with myelodysplastic syndromes (MDS).
Mechanism of Action (MOA)
Eltrombopag (Promacta) belongs to the class of medicines called thrombopoietin receptor (TPO) agonists. It activates thrombopoietin receptors in the bone marrow, stimulating the production of platelets.
By increasing platelet production, eltrombopag (Promacta) can help reduce the risk of bleeding in patients with low platelet counts. In patients with severe aplastic anemia, it may also improve red and white blood cell counts.
How Eltrombopag Copay Assistance Works
AmeriPharma® Specialty Pharmacy alleviates financial burdens for patients and their families
-
Advanced software locates funding sources to match you with top-dollar foundation programs
-
One of our copay assistance specialists will assist with the application process
-
Automatic updates will be sent to you and your physician on the status of the funding
Recommended Dosage
The dosage of eltrombopag (Promacta) varies depending on the condition being treated, the patient’s age, liver function, and response to treatment. Below are the recommended dosages for adult and pediatric patients indicated by the FDA.
Dosage for Persistent or Chronic ITP
The recommended starting dose for most adults and children aged 6 years and older with persistent or chronic ITP is 50 mg orally once daily. For children aged 1 to 5 years, the recommended starting dose is 25 mg once daily.
Dosage for Chronic Hepatitis C-associated Thrombocytopenia
For patients with chronic hepatitis C-associated thrombocytopenia, the recommended starting dose of Promacta is 25 mg orally once daily. The dose may be adjusted based on platelet counts and treatment response.
First-line Severe Aplastic Anemia
The dosage of Promacta in combination with standard immunosuppressive therapy for the treatment of severe aplastic anemia is as follows:
- For pediatric patients aged 2 to 5 years: Promacta orally once daily at 2.5 mg/kg
- For pediatric patients aged 6 to 11 years: one 75 mg tablet once a day
- For patients aged 12 years and older: 150 mg orally once daily, concurrently with standard immunosuppressive therapy.
Refractory Severe Aplastic Anemia
The recommended starting dosage for patients with refractory severe aplastic anemia is 50 mg orally once daily. The dose may be adjusted based on blood counts and treatment response.
Patients with liver problems or East- or Southeast-Asian ancestry may require a lower starting dose of Promacta. However, dosage adjustments vary depending on the condition being treated. Your healthcare provider will determine the appropriate dose and adjust it based on your response to treatment.
Eltrombopag Side Effects
Common side effects include:
- Low levels of red blood cells (anemia)
- Nausea
- Fever
- Abnormal liver function tests
- Cough
- Feeling tired
- Headache
- Diarrhea
- Rash
- Skin discoloration (hyperpigmentation)
Serious side effects include:
- Severe allergic reactions
- Liver damage (hepatotoxicity)
- High platelet counts and an increased risk of blood clots
- Worsening liver function in patients with chronic hepatitis C who receive Promacta with interferon and ribavirin
- Increased risk of cataracts or worsening progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML)
Insurances Accepted
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
Get Started in Minutes
Fill out your information and one of our specialists will call you ASAP.
How Much Can You Save?
Complete this form to save up to 100%!

By submitting, you agree to AmeriPharma’s Terms of Use, Privacy Policy, and Notice of Privacy Practices